Cytarabine/etidronic acid

Drug Profile

Cytarabine/etidronic acid

Alternative Names: Etidronate/cytosine arabinoside; Etidronic acid/cytarabine; MBC 11; MBC-11 -29

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MBC Pharma
  • Developer MBC Pharma; Osteros Biomedica
  • Class Antihypercalcaemics; Antineoplastics; Arabinonucleosides; Bisphosphonates; Calcium regulators; Drug conjugates; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone metastases

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Bone metastases presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Dec 2015 Osteros Biomedica completes a phase I trial in Bone metastases in Russia (IV) (NCT02673060)
  • 27 Oct 2014 Phase-I clinical trials in Bone metastases in Russia (IV) (NCT02673060)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top